Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
SLDB Solid Biosciences
- 5.0900
- -0.3300-6.09%
Close Mar 10 16:00 ET
- 4.9800
- -0.1100-2.16%
Pre 08:27 ET
394.44MMarket Cap-1.66P/E (TTM)
5.6000High4.9550Low1.74MVolume5.5200Open5.4200Pre Close8.93MTurnover3.82%Turnover RatioLossP/E (Static)77.49MShares15.050052wk High2.87P/B232.50MFloat Cap2.880052wk Low--Dividend TTM45.68MShs Float822.6000Historical High--Div YieldTTM11.90%Amplitude1.8100Historical Low5.1160Avg Price1Lot Size
Solid Biosciences Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -6.19%-100.01M | -42.37%-29.65M | -32.47%-23.71M | 21.84%-21.47M | 10.01%-25.19M | 3.88%-94.18M | 39.61%-20.82M | 12.39%-17.9M | -72.98%-27.47M | -2.96%-28M |
| Net income from continuing operations | -29.87%-124.7M | -109.47%-42.6M | -55.98%-32.73M | -1.80%-25.07M | 19.18%-24.3M | -11.67%-96.02M | -34.22%-20.34M | -2.79%-20.98M | 1.85%-24.63M | -18.72%-30.07M |
| Operating gains losses | --4.75M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -4.88%2.46M | 129.11%488K | -31.12%405K | 75.68%1.24M | -69.64%327K | 7.18%2.58M | -60.48%213K | 34.25%588K | -2.63%703K | 51.90%1.08M |
| Other non cash items | 165.16%7.7M | 150.68%2.57M | 529.18%3.99M | --1.24M | ---94K | 115.72%2.91M | 105.62%1.02M | --634K | ---- | ---- |
| Change In working capital | 132.14%2.85M | 184.79%2.13M | 132.46%2.84M | 101.17%78K | -142.32%-2.19M | -140.39%-8.87M | 14.68%-2.51M | 162.12%1.22M | -198.52%-6.67M | 83.71%-905K |
| -Change in prepaid assets | -508.86%-2.45M | 119.77%104K | -158.86%-993K | 87.99%-219K | -206.03%-1.34M | -83.82%598K | -233.50%-526K | -37.86%1.69M | -146.15%-1.82M | 137.46%1.26M |
| -Change in payables and accrued expense | 190.17%6.97M | 261.42%2.44M | 18,478.26%4.23M | 128.80%1.16M | 60.48%-856K | -1,419.28%-7.73M | 54.72%-1.51M | 99.51%-23K | -144.91%-4.03M | -479.14%-2.17M |
| -Change in other current liabilities | 3.40%-1.68M | 12.66%-414K | 10.36%-398K | ---- | ---- | ---1.74M | ---474K | ---444K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -6.19%-100.01M | -42.37%-29.65M | -32.47%-23.71M | 21.84%-21.47M | 10.01%-25.19M | 3.88%-94.18M | 39.61%-20.82M | 12.39%-17.9M | -72.98%-27.47M | -2.96%-28M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -266.02%-16.09M | -14.86%38.57M | 55.40%-10.99M | 89.27%-5.18M | -203.30%-38.49M | -83.62%9.69M | -31.47%45.3M | -265.24%-24.64M | 19.07%-48.23M | -1.28%37.26M |
| Net PPE purchase and sale | 57.16%-649K | -121.11%-199K | 96.08%-15K | 46.64%-286K | 70.55%-149K | 37.27%-1.52M | 89.49%-90K | -60.25%-383K | 52.82%-536K | -175.00%-506K |
| Net investment purchase and sale | -237.78%-15.44M | -14.57%38.77M | 54.76%-10.97M | 89.75%-4.89M | -201.54%-38.35M | -62.71%11.2M | 28.09%45.39M | -260.10%-24.25M | 18.41%-47.7M | -0.42%37.77M |
| Net other investing changes | ---- | ---- | --0 | --0 | --5K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -266.02%-16.09M | -14.86%38.57M | 55.40%-10.99M | 89.27%-5.18M | -203.30%-38.49M | -83.62%9.69M | -31.47%45.3M | -265.24%-24.64M | 19.07%-48.23M | -1.28%37.26M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 3,821.75%122.44M | 1,274.26%6.94M | 3.26M | 91.06%5M | 107.24M | -95.83%3.12M | -99.32%505K | 0 | 3,484.93%2.62M | 0 |
| Net issuance payments of debt | ---473K | ---128K | ---120K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net common stock issuance | 4,006.12%122.12M | 1,476.32%6.86M | ---2.01M | 110.99%5.36M | --111.92M | -95.90%2.97M | -99.40%435K | --0 | --2.54M | --0 |
| Proceeds from stock option exercised by employees | 436.49%794K | 201.43%211K | --278K | 97.44%154K | --151K | -27.09%148K | -35.78%70K | --0 | 6.85%78K | --0 |
| Net other financing activities | ---- | ---- | ---- | ---286K | ---4.83M | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 3,821.75%122.44M | 1,274.26%6.94M | --3.26M | 91.06%5M | --107.24M | -95.83%3.12M | -99.32%505K | --0 | 3,484.93%2.62M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -51.76%75.85M | 30.38%66.33M | 4.67%97.76M | -28.28%119.41M | -51.76%75.85M | 29.71%157.22M | 0.02%50.87M | 65.66%93.4M | 26.33%166.48M | 29.71%157.22M |
| Current changes in cash | 107.79%6.34M | -36.50%15.86M | 26.08%-31.44M | 70.38%-21.64M | 370.15%43.56M | -325.96%-81.37M | -76.51%24.98M | -670.37%-42.53M | 3.08%-73.08M | -12.39%9.27M |
| End cash Position | 8.36%82.19M | 8.36%82.19M | 30.38%66.33M | 4.67%97.76M | -28.28%119.41M | -51.76%75.85M | -51.76%75.85M | 0.02%50.87M | 65.66%93.4M | 26.33%166.48M |
| Free cash flow | -5.19%-100.67M | -42.73%-29.85M | -29.78%-23.72M | 22.31%-21.75M | 11.09%-25.34M | 5.24%-95.7M | 40.82%-20.91M | 14.05%-18.28M | -64.58%-28M | -4.12%-28.5M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |